



12

EUROPEAN PATENT SPECIFICATION

- 45 Date of publication of patent specification: **12.04.95** 51 Int. Cl.⁶: **C07D 211/46**, A61K 49/00,
C07D 265/30, C07D 207/12,
21 Application number: **90901813.7** C07D 241/04, C07D 279/12,
22 Date of filing: **15.01.90** A61K 51/00, A61K 49/04
- 86 International application number:
PCT/EP90/00079
- 87 International publication number:
WO 90/08138 (26.07.90 90/17)

The file contains technical information submitted after the application was filed and not included in this specification

54 **HETEROCYCLIC CHELATING AGENTS.**

- 30 Priority: **13.01.89 GB 8900719**
- 43 Date of publication of application:
23.10.91 Bulletin 91/43
- 45 Publication of the grant of the patent:
12.04.95 Bulletin 95/15
- 84 Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI LU NL SE
- 56 References cited:
EP-A- 71 564
EP-A- 130 934
EP-A- 250 358
- 73 Proprietor: **NYCOMED IMAGING AS**
Nycoveien 2,
Postboks 4220,
Torshov
N-0401 Oslo 4 (NO)

- 72 Inventor: **ALMEN, Torsten**
Ynglingeget 7B
S-217 74 Malmö (SE)
Inventor: **BERG, Arne**
Stasjonveien 39B
N-1310 Blommenholm (NO)
Inventor: **DUGSTAD, Harald**
Tore Hunds vei 6
N-0576 Oslo 5 (NO)
Inventor: **KLAVENESS, Jo**
Sk yen Terrasse 15
N-0276 Oslo 2 (NO)
Inventor: **KRAUTWURST, Klaus, Dieter**
Trudvangveien 35C
N-1320 Stabekk (NO)
Inventor: **RONGVED, Pal**
Hovdens vei 11
N-1457 Hellvik (NO)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 452 392 B1

EP 0 452 392 B1

⑦⁴ Representative: **Cockbain, Julian, Dr. et al**
Frank B. Dehn & Co.
Imperial House
15-19, Kingsway
London WC2B 6UZ (GB)

Description

The present invention relates to certain novel chelating agents, in particular heterocyclic polyamines, and to their uses, especially their medical uses.

5 The medical use of chelating agents is well established, for example as stabilizers for pharmaceutical preparations, as antidotes for poisonous heavy metal species and as diagnostic agents for the administration of metal species (e.g. ions or atoms) for diagnostic techniques such as X-ray, magnetic resonance imaging (MRI) or ultrasound imaging or scintigraphy.

Polyamine chelating agents, for example aminopoly-(carboxylic acid or carboxylic acid derivative) (hereinafter APCA) chelating agents and their metal chelates, are well known and are described for example 10 in US-A-2407645(Bersworth), US-A-2387735 (Bersworth), EP-A-71564 (Schering), EP-A-130934 (Schering), EP-A-165728 (Nycomed AS), DE-A-2918842 (Rexolin Chemicals AB), DE-A-3401052 (Schering), EP-A-258616 (Salutar), DE-A-3633245 (Schering), EP-A-263059 (Schering), EP-A-277088 (Schering) and DE-A-3633243 (IDF).

15 Thus, for example, EP-A-71564 describes paramagnetic metal chelates, for which the chelating agent is nitrilotriacetic acid (NTA), N,N,N',N'-ethylenediamine-tetraacetic acid (EDTA), N-hydroxyethyl-N,N',N'-ethylenediamine-triacetic acid (HEDTA), N,N,N',N'',N''-diethylenetriamine-pentaacetic acid (DTPA) and N-hydroxyethylimino-diacetic acid, as being suitable as contrast agents for MRI, contrast being achieved by the effect of the magnetic field of the paramagnetic species (e.g. Gd(III)) with the chelating agents serving 20 to reduce the toxicity and to assist administration of that paramagnetic species.

Amongst the particular metal chelates disclosed by EP-A-71564 was Gd DTPA, the use of which as an MRI contrast agent has recently received much attention. The Gd(III) chelate of 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), referred to in DE-A-3401052 (Schering) and in US-A-4639365 (University of Texas), has also recently received attention in this regard.


25 To improve stability, water solubility and selectivity, relative to the APCA chelating agents described in EP-A-71564, Schering, in EP-A-130934, have proposed the partial substitution for the N-attached carboxylalkyl groups of alkyl, alkoxyalkyl, alkoxyalkylalkyl or alkylaminocarbonylalkyl groups, where any amide nitrogens may themselves carry polyhydroxyalkyl groups. More recently, to improve compatibility, stability, solubility and selectivity, in EP-A-250358 Schering have proposed a narrow range of compounds having a 30 DTPA-like structure including a bridging alkylene chain. Thus EP-A-250358 specifically discloses several 2,6-bis-aminomethyl-1-piperidine compounds.

However, all hitherto known APCA chelating agents and their metal chelates encounter problems of toxicity, stability or selectivity and there is thus a general and continuing need for such polyamine chelating agents which form metal chelates of reduced toxicity, improved stability or improved water solubility.

35 Nycomed, in European Patent Application No. EP-A-299795 suggest that the toxicity of certain APCA chelating agents and their chelates may be reduced by introducing at least one hydrophilic moiety as a substituent on one or more of the alkylene bridges between the amine nitrogens.

We now propose a novel class of polyamine chelating agents which incorporate within their structure a 5- or 6-membered saturated heterocyclic ring and carry hydrophilic moieties on or in the ring or on the 40 alkylene bridges between the amine nitrogens.

Thus viewed from one aspect the present invention provides a compound of formula I




(wherein X represents a bond, an oxygen or sulphur atom or a group of formula CHR¹ or NR³;

55 each R¹ which may be the same or different represents a hydrogen atom, a group of formula OR³ or NR³R³ or a C₁₋₈alkyl or (C₁₋₈alkoxy)-C₁₋₈alkyl group optionally substituted by a hydroxyl group or by a group of formula NR³R³ or CONR³R³;

each R² which may be the same or different represents a hydrogen atom or a C₁₋₈alkyl or C₁₋₈alkoxy group optionally mono- or poly- substituted by hydroxyl or C₁₋₈alkoxy groups;

each R^3 which may be the same or different represents a hydrogen atom, an optionally mono- poly-hydroxylated C_{1-8} alkyl group or a group of formula CH_2Y ;
 Y represents a group of formula COZ , $CON(OH)R^4$, POZ_2 or SO_2Z ; and
 Z represents a group of formula OR^4 , NR^4R^4

5 or



where each R^{11} which may be the same or different is a hydrogen atom, a hydroxyl group or an optionally hydroxylated C_{1-8} alkyl group,

20 s is 0, 1 or 2, and

W is a group CHR^{11} , NR^{11} or an oxygen atom; and

each R^4 which may be the same or different represents a hydrogen atom or an optionally mono- or polyhydroxylated C_{1-8} alkyl, $(C_{1-8}alkoxy)-C_{1-8}alkyl$ or $poly(C_{1-8}alkoxy)C_{1-8}alkyl$ group; with the proviso that where s is 0 then in the resultant 5 membered heterocyclic ring W is a CHR^{11} group and that where X represents a bond or a group CHR^1 at least one group R^1 or R^2 represents other than a hydrogen atom or an unsubstituted C_{1-8} alkyl group) or a chelate complex or salt thereof.

25 Thus, for example, in the compounds of formula I, Z may represent a group of formula OR^4 or NR^4_2 and each R^4 which may be the same or different may represent a hydrogen atom or an optionally hydroxylated alkyl group.

30 In the compounds of the invention, alkyl or alkylene moieties in groups R^1 to R^4 and R^{11} , unless otherwise stated, may be straight chained or branched and preferably contain from 1 to 6 and most preferably 1 to 4, carbon atoms. Where substituents may themselves optionally be substituted by hydroxyl or alkoxy groups, this may be monosubstitution or polysubstitution and in the case of polysubstitution alkoxy or hydroxyl substituents may be carried by alkoxy substituents.

35 Where the compounds of the invention incorporate one or more hydrophilic R^1 or R^2 groups, these are preferably straight-chained or branched moieties having a carbon atom content of from 1 to 8, especially preferably 1 to 6, carbon atoms. The hydrophilic groups may be alkoxy, polyalkoxy, hydroxyalkoxy, hydroxypolyalkoxy, polyhydroxyalkoxy, polyhydroxylated polyalkoxy, hydroxyalkyl, polyhydroxyalkyl, alkoxyalkyl, polyalkoxyalkyl, hydroxylated alkoxyalkyl, polyhydroxylated alkoxyalkyl, hydroxylated polyalkoxyalkyl, or polyhydroxylated polyalkoxyalkyl groups. More preferably however they will be monohydroxyalkyl or polyhydroxyalkyl groups. The hydrophilic groups serve to increase the hydrophilicity and reduce the lipophilicity of the metal chelates formed with the chelating agents of the invention and it is preferred that the compounds of formula I should contain at least 1, conveniently from 1 to 4, and preferably 1, 2 or 3 hydrophilic R^1 or R^2 groups. As hydrophilic groups, the compounds of the invention may thus include for


40 example hydroxymethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl, 1-(hydroxymethyl)-2-hydroxyethyl, methoxymethyl, ethoxymethyl, 2-hydroxyethoxymethyl, methoxyethoxymethyl, (2-hydroxy-ethoxy)ethyl, etc, groups.

Where a group Z in a compound according to the invention is a nitrogen attached heterocyclic ring, it particularly preferably is of formula

50

55


5



10

In the compounds of formula I, the groups Y preferably represent carboxylic acid or amide groups, for example groups of formula COOH, CONH₂,

15



CONHR^{4''} or CONR^{4''}₂ (where R^{4''} is an alkyl or mono or poly hydroxyalkyl group, for example a C₁₋₆ alkyl group optionally carrying 1, 2, 3 or 4 hydroxyl groups). Particularly preferably, the terminal amine nitrogens, i.e. those carrying two CH₂Y groups, will carry a CH₂Y group in which Y is an amide group. Where Y is a carboxyl group, the compounds of formula I can conveniently form salts or chelates in which Y represents -COOM (wherein M⁺ is a monovalent cation or a fraction of a polyvalent cation, for example an ammonium or substituted ammonium ion or a metal ion, for example an alkali metal or alkaline earth metal ion). Particularly preferably, M⁺ is a cation deriving from an organic base, for example meglumine or lysine. In such salts or chelates one or more (but not necessarily all) of the carboxyl groups are transformed into COOM groups.

It is particularly preferred that the number of the ion-forming groups Y in the compounds of formula I be chosen to equal the valency of the metal species to be chelated by the compound formula I. Thus, for example, where Gd(III) is to be chelated, the compound of formula I (or salt thereof) preferably contains three ion-forming Y groups, for example -COOH (or -COOM). In this way, the metal chelate will be formed as a neutral species, a form preferred since the osmotic pressures in concentrated solutions of such compounds are low and since their toxicities relative to their ionic analogues are significantly reduced.

Compounds of formula I in which all the Y groups carboxyl are -COOH groups or salts or amides of such compounds are especially preferred since compositions containing metal chelates of such compounds can readily be sterilized, for example by autoclaving.




Included amongst the particularly preferred compounds according to the invention are those of formula I wherein R¹ represents a hydrogen atom, a hydroxyl group or a hydroxylated alkyl group, R² represents a hydrogen atom or a hydroxylated alkyl group, R³ represents a hydrogen atom or a group of formula CH₂Y, X represents a bond, an oxygen atom, an optionally hydroxylated methylene group or a group NR³, Y represents a group of formula COZ and Z represents a hydroxyl group or a group NHR^{4'} (where R^{4'} represents a hydrogen atom or an optionally hydroxylated alkyl group) and metal chelates and salt thereof.

45


50

55

Especially preferred compounds according to the invention include those of the following formulae:



40 (where R⁵ represents CH₂COOH, R⁶ represents CH₂COOH, CH₂CON(CH₃)CH₂CHOHCH₂OH, or CH₂CONHR⁷ and R⁷ represents CH₃, CH₂CHOHCH₂OH or CH(CH₂OH)₂, or NR⁵R⁶ represents a group







where W represents an oxygen atom or a group CH₂ or CHO, s is 0 or 1 and R¹¹ is hydrogen or where s is 1 and W is oxygen each R¹¹ may also represent a C₁₋₄ hydroxyalkyl group) and the metal chelates and the salts thereof.

50

55


Particularly preferred compounds according to the invention include those of formulae:



(where R^{15} is $NHCH_3$ or $N(CH_3)CH_2CHOHCH_2OH$) and the chelates, e.g. with Gd^{3+} , and salts thereof.


45 Viewed from a further aspect, the invention also provides a process for the preparation of the compounds of the invention, said process comprising one or more of the following steps:

a) reacting a compound of formula II



(wherein X, R¹ and R² are as hereinbefore defined and R¹⁰ represents a hydrogen atom or a group CH₂Y where Y is as hereinbefore defined, with the proviso that at least one hydrogen is nitrogen-attached) with a compound serving to replace a nitrogen attached hydrogen by a group CH₂Y, e.g. a compound of formula III

5




(where L is a nucleophilic leaving group, e.g. a halogen atom, such as chlorine, bromine or iodine); and b) converting a compound of formula I into a chelate complex or salt thereof.

10

The compounds of formula II may be prepared from unsaturated starting compounds of formula IV

15




20

(wherein R⁸ represents a hydroxyl group or a group of formula NR⁹ and each R⁹ which may be the same or different represents a hydrogen atom or an optionally hydroxylated alkyl group) by i) catalytic reduction of the heterocyclic ring, ii) (where required) amide formation, and iii) reduction of amide functions to amines (optionally involving substituting the carbon of the carboxyl groups shown in formula II with groups R²). These process stages need not be performed in this order.

25

The following schemes for the preparation of compounds of formula I are provided by way of illustration:

30





35

40

45


50

55



15

The starting compound (1) is described by Wahlstroem in Arkiv Kemi 11 (1957)251. Catalytic reduction
amidation, reduction and alkylation yields the compound (5) which is a compound according to the
invention.



30


The starting compound (6) is described by Eremev in Zh. Org. Chim. 21 (1985)2239. Alkylation yields
compound (7) which is a compound according to the invention.

40


45

50


55



The starting compound (8) is described by Williams et al. in J. Org. Chem. 37 (1972)2963. Amidation, reduction and alkylation yields compound (11) which is a compound according to the invention.



The starting compound (12) may be prepared analogously to compounds described by Acton et al. in J. Med. Chem. 27 (1984)638. Deprotection, hydrolysis, reduction and alkylation yields compound (16) which is a compound according to the invention.



30


The starting compound (17) is described by Hermann et al. in *Helv. Chim. Acta* **59** (1976)626. Amidation, reduction and alkylation yields compound (20) which is a compound according to the invention.

The introduction of a CH₂Y moiety other than an acetic acid residue may for example be performed as follows:

35

a) To introduce a phosphonic acid moiety, the general method for synthesis of alpha-aminophosphonic acids described by K.Moedritzer et al. in *J.Org.Chem* **31** (1966) 1603 may be used.

40



45

(21)

(22)

(of formula II)


(of formula I)

50

(where R₂⁺ NCH₂Y is a compound of formula I).


55

b) To introduce a hydroxamic acid moiety, the general method for transformation of an activated acid derivative into hydroxamic acid described by P.N.Turowski et al. in *Inorg. Chem.* **27** (1988) 474 may be used.



15 (where $R^*N(CH_2COOH)CH_2Y$ is a compound of formula I).

c) To introduce a sulfonic acid moiety, synthesis may be performed by alkylation of an amino function for example with iodomethanesulfonic acid



30 (where $R_2^*NCH_2SO_3H$ is a compound of formula I).

As mentioned above, the starting materials for the preparation of compounds of formula II may conveniently be unsaturated, e.g. aromatic, heterocycles. Procedures for the catalytic reduction of aromatic heterocycles are described by Nishiki et al. in *Tetrahedron Letters* 23 (1982)193 and by Kaiser in *J.Org. Chem.* 49 (1984) 4203 and elsewhere.

35 Conversion of hydroxyl groups to groups R^3 or R^4 can be by conventional methods, e.g. by alkylation.

Amide derivatives of formula I may be produced from the oligo acids by methods analogous to those of EP-A-250358 or of EP-A-299795.

40 Compounds of formula I wherein Y is a phosphonic group may be synthesized by reacting the amines of formula II with formaldehyde/phosphorous acid, e.g. as described by Moedritter in *J.Org.Chem.* 31 (1966) 1603. Similarly compounds of formula I, wherein Y is a hydroxamic or sulphonic acid group, can be synthesized as described by Turowski et al. in *Inorg. Chem.* 27 (1988) 474 or by amine reduction using iodomethanesulphonic acid.

45 Chelants of formula I may be used as the basis for bifunctional chelants or for polychelant compounds, that is compounds containing several independant chelant groups, by substituting for one Y or R^1 or R^2 group a bond or linkage to a macromolecule or polymer, e.g. a tissue specific biomolecule or a backbone polymer such as polylysine or polyethyleneimine which may carry several chelant groups and may itself be attached to a macromolecule to produce a bifunctional-polychelant. Such macromolecular derivatives of the compounds of formula I and the metal chelates and salts thereof form a further aspect of the present invention.

50 The linkage of a compound of formula I to a macromolecule or backbone polymer may be effected by any of the conventional methods such as the mixed anhydride procedure of Krejcarek et al. (see *Biochemical and Biophysical Research Communications* 77: 581 (1977)), the cyclic anhydride method of Hnatowich et al. (see *Science* 220: 613 (1983) and elsewhere), the backbone conjugation techniques of Meares et al. (see *Anal. Biochem.* 142: 68 (1984) and elsewhere) and Schering (see EP-A-331616 for example) and by the use of linker molecules as described for example by Nycomed in WO-A-89/06979.

Salt and chelate formation may be performed in a conventional manner.

The chelating agents of the present invention are particularly suitable for use in detoxification or in the formation of metal chelates, chelates which may be used for example in or as contrast agents for in vivo or

in vitro magnetic resonance (MR), X-ray or ultrasound diagnostics (e.g. MR imaging and MR spectroscopy), or scintigraphy or in or as therapeutic agents for radiotherapy, and such metal chelates form a further aspect of the present invention.

5 Salts or chelate complexes of the compounds of the invention containing a heavy metal atom or ion are particularly useful in diagnostic imaging or therapy. Especially preferred are salts or complexes with metals of atomic numbers 20-32,42-44 49 and 57 to 83.

For use as an MR-diagnostics contrast agent, the chelated metal species is particularly suitably a paramagnetic species, the metal conveniently being a transition metal or a lanthanide, preferably having an atomic number of 21-29, 42, 44 or 57-71. Metal chelates in which the metal species is Eu, Gd, Dy, Ho, Cr, 10 Mn or Fe are especially preferred and Gd^{3+} , Mn^{2+} and Dy^{3+} are particularly preferred. For such use, the paramagnetic metal species is conveniently non-radioactive as radioactivity is a characteristic which is neither required nor desirable for MR-diagnostics contrast agents. For use as X-ray or ultrasound contrast agents, the chelated metal species is preferably a heavy metal species, for example a non-radioactive metal with an atomic number greater than 37, preferably greater than 50, e.g. Dy^{3+} .

15 For use in scintigraphy and radiotherapy, the chelated metal species must of course be radioactive and any conventional complexable radioactive metal isotope, such as ^{99m}Tc or ^{111}In for example, may be used. For radiography, the chelating agent may be in the form of a metal chelate with for example ^{67}Cu .

For use in detoxification of heavy metals, the chelating agent must be in salt form with a physiologically acceptable counterion, e.g. sodium, calcium, ammonium, zinc or meglumine, e.g. as the sodium salt of the 20 chelate of the compound of formula I with zinc or calcium.

Where the metal chelate carries an overall charge, such as is the case with the prior art Gd DTPA, it will conveniently be used in the form of a salt with a physiologically acceptable counterion, for example an ammonium, substituted ammonium, alkali metal or alkaline earth metal cation or an anion deriving from an inorganic or organic acid. In this regard, meglumine salts are particularly preferred.

25 Viewed from a further aspect, the present invention provides a diagnostic or therapeutic agent comprising a metal chelate, whereof the chelating entity is the residue of a compound according to the present invention, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation therewith or for inclusion in a pharmaceutical formulation for human or veterinary use.

30 Viewed from another aspect, the present invention provides a detoxification agent comprising a chelating agent according to the invention in the form of a weak complex or salt with a physiologically acceptable counterion, together with at least one pharmaceutical or veterinary carrier or excipient, or adapted for formulation therewith or for inclusion in a pharmaceutical formulation for human or veterinary use.

35 The diagnostic and therapeutic agents of the present invention may be formulated with conventional pharmaceutical or veterinary formulation aids, for example stabilizers, antioxidants, osmolality adjusting agents, buffers, pH adjusting agents, etc. and may be in a form suitable for parenteral or enteral administration, for example injection or infusion or administration directly into a body cavity having an external escape duct, for example the gastrointestinal tract, the bladder or the uterus. Thus the agent of the present invention may be in a conventional pharmaceutical administration form such as a tablet, capsule, 40 powder, solution, suspension, dispersion, syrup, suppository, etc; however, solutions, suspensions and dispersions in physiologically acceptable carrier media, for example water for injections, will generally be preferred.

Where the agent is formulated for parenteral administration, the carrier medium incorporating the chelate or the chelating agent salt is preferably isotonic or somewhat hypertonic.

45 Where the diagnostic or therapeutic agent comprises a chelate or salt of a toxic metal species, e.g. a heavy metal ion, it may be desirable to include within the formulation a slight excess of the chelating agent, e.g. as discussed by Schering in DE-A-3640708, or more preferably a slight excess of the calcium salt of such a chelating agent.

50 For MR-diagnostic examination, the diagnostic agent of the present invention, if in solution, suspension or dispersion form, will generally contain the metal chelate at concentration in the range 1 micromole to 1.5 mole per litre, preferably 0.1 to 700mM. The diagnostic agent may however be supplied in a more concentrated form for dilution prior to administration. The diagnostic agent of the invention may conveniently be administered in amounts of from 10^{-3} to 3 mmol of the metal species per kilogram of body weight, e.g. about 1 mmol Dy/kg bodyweight.

55 For X-ray examination, the dose of the contrast agent should generally be higher and for scintigraphic examination the dose should generally be lower than for MR examination. For radiotherapy and detoxification, conventional dosages may be used.

Viewed from a further aspect, the present invention provides a method of generating enhanced images of the human or non-human animal body, which method comprises administering to said body a diagnostic agent according to the present invention and generating an X-ray, MR-diagnostics, ultrasound or scintigraphic image of at least a part thereof.

5 Viewed from a further aspect, the present invention provides a method of radiotherapy practised on the human or non-human animal body, which method comprises administering to said body a chelate of a radioactive metal species with a chelating agent according to the invention.

Viewed from a further aspect, the present invention provides a method of heavy metal detoxification practised on the human or non-human animal body, which method comprises administering to said body a
10 chelating agent according to the invention in the form of a weak complex or salt with a physiologically acceptable counterion.

Viewed from a yet further aspect, the present invention also provides the use of the compounds, especially the metal chelates, according to the invention for the manufacture of diagnostic or therapeutic agents for use in methods of image generation, detoxification or radiotherapy practised on the human or
15 non-human animal body.

Viewed from a still further aspect, the present invention provides a process for the preparation of the metal chelates of the invention which process comprises admixing in a solvent a compound of formula I or a salt (e.g. the sodium salt) or chelate thereof together with an at least sparingly soluble compound of said metal, for example a chloride, oxide or carbonate.

20 Viewed from a yet still further aspect, the present invention provides a process for the preparation of the diagnostic or therapeutic agent of the present invention, which comprises admixing a metal chelate according to the invention, or a physiologically acceptable salt thereof, together with at least one pharmaceutical or veterinary carrier or excipient.

Viewed from a yet still further aspect, the present invention provides a process for the preparation of
25 the detoxification agent of the invention, which comprises admixing a chelating agent according to the invention in the form of a salt with a physiologically acceptable counterion together with at least one pharmaceutical or veterinary carrier or excipient.

The disclosures of all of the documents mentioned herein are incorporated by reference.

30 The present invention will now be illustrated further by the following Examples. All ratios and percentages given herein are by weight and all temperatures are in degrees Celsius unless otherwise indicated.

Example 1

35 2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-pentakiscarboxymethyl-piperidine

(a) Chelidamic acid-diethylester

40 Chelidamic acid (25g, 0.136 mol) and 500 ml of ethanol were refluxed while dry hydrogen chloride was bubbled through the suspension. The resultant clear solution was concentrated in vacuo and crystallised from water to give 25.0g (77%) white crystals, M.P. 123-124 °C. ¹³C-NMR (CDCl₃) delta = 14.01 (CH₃); 63.0 (CH₂); 118.31(CH); 162.95(C=O).

b) Chelidamic acid-diamide

45 Chelidamic acid-diethylester (3g, 0.013 mol) was dissolved in 45 ml of equal parts of methanol and concentrated aqueous ammonia and heated in a pressure bottle at 100 °C for 72 hours. The resulting solution was concentrated and recrystallized from dilute aqueous ammonia/methanol. Yield: 1.3g(58 %), M.P. 330-335 °C. FAB-MS: 182(m + 1).

50 c) 2,6-Bis-aminocarbonyl-4-hydroxy-piperidine

A solution of chelidamic acid diamide (0.38 g/2.1 mmol) in absolute ethanol (100 ml) was hydrogenated at 65 °C under 3 atmospheres pressure hydrogen in the presence of 5 % rhodium on carbon (0.22 g). After
55 17 hours, the catalyst was removed by filtration and the solvent was evaporated. The residue was dissolved in water (50 ml). The suspension was filtered and the filtrate was evaporated to dryness to give the title compound. Yield: 0.21 g (53.4 %). The structure was confirmed by ¹³C-NMR (300 MHz, DMSO-d₆): 35.33, 55.58, 65.31, 166.57 ppm.

d) 2,6-Bis-aminomethyl-4-hydroxy-piperidine trihydrochloride

2,6-Bis-aminocarbonyl-4-hydroxy-piperidine (0.21 g/0.11 mmol) was dissolved in tetrahydrofuran (THF), and a solution of borane in THF (20ml, 1M/20 mmol) was added. The mixture was refluxed overnight and methanol (5ml) was then added at 0 °C. The solvents were removed. Methanol (5 ml) was again added, and the solution was evaporated to near dryness. The residue was taken up in dry ethanol (20ml), saturated with HCl (g) and heated at reflux for two hours. The reaction mixture was concentrated and cooled to 0 °C. The crystalline product was collected and dried under vacuum.
Yield: 0.21 g (71%). MS (IP 70 eV, Cl-NH₃): [M + 1] = 160.

(e) 2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidine

2,6-Bis-aminomethyl-4-hydroxy-piperidine trihydrochloride (10mmol) is dissolved in water (10ml). The pH is adjusted to 10 with 4 M LiOH, and a solution of bromoacetic acid (55 mmol) and LiOH (55 mmol) in water (10 ml) is gradually added to the stirred mixture at ambient temperature. The temperature is gradually increased to 85 °C during 4 hours while the pH is kept in the alkaline range (8 to 10) with aqueous LiOH. The solution is allowed to cool to ambient temperature, neutralised with conc. hydrobromic acid, loaded on a strong cation exchanger (AG 5Wx4) and eluted with 6M aqueous ammonia. After evaporation down, the crude product is dissolved in water and lyophilised to yield the title compound.

Example 23,5-Thiomorpholinodimethaneamine penta (acetic acid)

3,5-Thiomorpholinodimethaneamine (10 mmol) (as described by A.V.Eremev in Zh. Org. Khim 21 - (1985) 2239) is dissolved in water (10 ml). The pH is adjusted to 10 with 4 M LiOH, and a solution of bromoacetic acid (55 mmol) and LiOH (55 mmol) in water (10 ml) is gradually added to the stirred mixture at ambient temperature. The temperature is gradually increased to 85 °C during 4 hours while the pH is kept in the alkaline range (8 to 10) with aqueous LiOH. The solution is allowed to cool to ambient temperature, neutralised with conc. hydrobromic acid, loaded on a strong cation exchanger (AG 5Wx4) and eluted with 6M aqueous ammonia. After evaporation down, the crude product is dissolved in water and lyophilised to yield the title compound.

Example 32,6-Bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidinea) 2,6-Bis-ethyloxycarbonyl-4-hydroxy-piperidine

The diester prepared as in Example 1a (20.0 g, 83.6 mmol) was dissolved in dry ethanol (200 ml). The solution was hydrogenated at 10 bar in the presence of rhodium on alumina (4.0 g) at 67 °C for 20 hours. After cooling, the solution was filtered and evaporated to give a yellow oil. The crude oil was purified by reverse phase chromatography to yield 10.8 g (53 %) of a yellow oil, FAB/MS: 246 (M + 1). NMR confirmed the structure.

b) 2,6-Bis-aminocarbonyl-4-hydroxy-piperidine

The diester from Example 3a (9.9 g, 40.5 mmol) was dissolved in 140 ml 4M ammonia in dry ethanol and placed in an autoclave. After 2 days stirring at 100 °C, the solution was cooled, the white precipitate was filtered off and washed with dry ethanol. Drying in vacuo yielded 5.6g (74%) of a white solid, mp. 252-256 °C, FAB/MS: 188 (M + 1). NMR confirmed the structure.

c) 2,6-Bis-aminomethyl-4-hydroxy-piperidine trihydrochloride

The diamide from Example 3b (5.5 g, 29.4 mmol) was suspended in 1 M borane in THF (590 ml) at 0 °C under nitrogen. After 1 hour with stirring, the colourless solution was refluxed overnight and cooled to ambient temperature. Methanol (590 ml) was added carefully. The solution was evaporated to a clear oil and methanol (275 ml) and conc. HCl (11 ml) were added. After refluxing for 2 hours the solution was

evaporated and the residue dissolved in 200 ml distilled water. The water phase was washed with 2 x 100 ml chloroform and evaporated to yield the title compound, 6.8 g (86%) white crystals, FAB/S: 160 (M + 1), 268 (M 3HCl). NMR confirmed the structure.

5 d) 2,6-Bis-aminomethyl-4-hydroxy-N, N',N''-pentakis-carboxymethyl-piperidine

Alternative A:

10 The amine hydrochloride from Example 3c (5.0 g, 18.6 mmol) was suspended in dry acetone with dry potassium carbonate (30.9 g, 223 mmol) under nitrogen and stirred vigorously for 30 min. A solution of t-butyl bromoacetate (21.8 g, 111.7 mmol) in 20 ml acetone was added slowly, and the reaction was stirred overnight. Another 15 g of potassium carbonate was added and the reaction was refluxed for 3 hours. After cooling, the reaction was filtered and the filtrate evaporated to a brownish oil, which was chromatographed on silica to yield 8.5 g of a yellow oil, FAB/MS: 730 (M + 1).

15 It was dissolved in 100 ml methylenechloride, and 100 ml trifluoroacetic acid was added slowly. After stirring for 3 hours, the solution was evaporated to an oil. This was stirred in ether for an ambient time and the solid filtered off and dried to yield 5.3 g (63 %) of a yellow solid, FAB/MS: 472 (M-Na).

Alternative B:

20 The amine hydrochloride from Example 3c (5.0 g, 18.6 mmol) was dissolved in water and the pH was adjusted to 9 with 4 M LiOH. Bromoacetic acid (16.5 g, 118.7 mmol) was carefully converted to the Li-salt with LiOH and added to the amine with stirring, the pH was kept between 9 and 10. After 3 hours the reaction was warmed to 80 °C for 5 hours, and then left stirring overnight at room temperature at pH 9.5.
25 The reaction mixture was treated with a Dowex 50W x 4 ion exchanger in water for 2 hours. The resin was separated from the solvent, washed with water and treated with 25% ammonia in water for 1 hour. The resin was separated, and evaporation of the solution yielded 4.6 g (55%) yellow solid. FAB/MS: 450 (M + 1).

Example 4

30 2, 6-Bis-aminomethyl-4-hydroxy-N,N', N''-tris-carboxymethyl-N,N''-bis-methylaminocarbonylmethyl-piperidine

35 The solid from Example 3d A (1.05 g, 2.2 mmol) was dissolved in dry pyridine (7.5 ml) under nitrogen and acetic anhydride (0.75 ml, 7.94 mmol) was added slowly. After 2.5 hours 30 ml of dry ether was added and the precipitate was separated by decantation and washing with ether. The solid was added to 30 ml methylamine (40 %) in water and the reaction was stirred overnight. After evaporation the crude product was dissolved in 25 ml distilled water and the pH was adjusted to 3.0 with 1M HCl. Ethanol-isopropanol in a 1:1 mix was added until precipitation was complete. The solid was filtered off and dried to yield a yellow
40 solid, 0.58 g (56 %). FAB/MS: 475 (M).

Example 4.1

45 2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-dimethylaminocarbonylmethyl-piperidine

The bis-dimethylamide was prepared analogously to the description in Example 4 by reacting the same amount of dimethylamine with the solid from Example 3d to yield 0.62g (56%). FAB/MS: 503 (M).

50 Example 4.2

2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-(methyl-(2,3-dihydroxypropyl))-aminocarbonylmethyl-piperidine

55 The bis-methylaminopropanediolamide was prepared analogously to the description in Example 4 by reacting the same amount, up to the point where the methylamine (40 %) in water was added. Methylaminopropanediol (2 equivalents) in 20 times the weight of the amine in dry dimethylacetamide was added under nitrogen and the reaction was stirred overnight at ambient temperature. Evaporation of solvent

yielded a yellow oil, which was treated analogously to Example 4. FAB/MS: 623 (M + 1).

Example 5

5 3,5-Bis-aminomethyl-N,N,N',N'',N'''-pentakis-carboxymethyl-morpholine.

a) 3-Carboxamido-5-cyano-4-benzylmorpholine

10 Benzylamine (19.3 g, 180 mmol) was dissolved in water (250 ml). The pH was adjusted to neutral by adding 6M HCl. Water (1500 ml) was added and the solution cooled on an ice/water mix. Sodium cyanide (17.6 g, 360 mmol) was dissolved in water (50 ml) and added to the solution. 2,2'-Oxybisacetaldehyde (18.4 g, 180 mmol) (prepared in accordance with J. Med. Chem. 27 638 (1984)) was dissolved in water (200 ml) and then added dropwise. The mixture was stirred for 1 hour at ambient temperature and left at 0 °C overnight. This gave a white precipitate which was filtered off and treated with THF (50 ml). The THF phase
15 was cooled and the title compound was precipitated. Yield: 10.4 g (24 %). FAB/MS: 246 (M + 1)

b) 3,5-Bis-aminomethyl-4-benzylmorpholine.

20 Lithium aluminium hydride (10 g, 264 mmol) was suspended in 200 ml dry THF and cooled to 0 °C under nitrogen. 3-Carboxamido-5-cyano-4-benzylmorpholine (4.3 g, 17.6 mmol), dissolved in dry THF (200 ml), was added dropwise. The mixture was refluxed for 48 hours, then cooled to 0 °C and water (10 g), 15% NaOH solution (10 g) and water (10 g) were added dropwise. The mixture was stirred for 30 min at ambient temperature, filtered and evaporated to dryness. 6 M HCl was then added and the mixture evaporated to dryness. The crude product was recrystallized from absolute ethanol and isolated as the hydrochloride salt.
25 Yield: 3.6 g (59%). FAB/MS: 236 (M + 1).

c) 3,5-Bis-aminomethyl-morpholine.

30 3,5-Bis-aminomethyl-4-benzylmorpholine (1.3 g, 5.5 mmol) was dissolved in methanol (50 ml). Ammoniumformiate (1.4 g, 22 mmol) and palladium on activated carbon (10 %, 5 g) were added. The reaction mixture was stirred at 50 °C under nitrogen for 3 hours. The catalyst was then filtered off and washed with several small portions of methanol and the solution evaporated to dryness. The tri-amine was used directly in the next reaction step. FAB/MS: 146 (M + 1).

35 d) 3,5-Bis-aminomethyl-N,N,N',N'',N'''-tert-butylpentakis-carboxymethyl-morpholine

3,5-Bis-aminomethyl-morpholine (0.36 g, 2.5 mmol), triethylamine (TEA) (2.53 g, 25 mmol) and tertbutyl bromoacetate (4.88 g, 25 mmol) were stirred at ambient temperature in dichloromethane overnight. The reaction mixture was diluted with chloroform and washed 3 times with water. The organic phase was dried
40 (MgSO₄) and the title compound isolated after purification on a silica column; solvent ethylacetate. Yield: 0.90 g (50%). FAB/MS: 717 (M + 1).

e) 3,5-Bis-aminomethyl-N,N,N',N'',N'''-pentakis-carboxymethyl-morpholine

45 The tert-butyl protected pentaacid from Example 5d (1.0 g, 1.4 mmol) was dissolved in a mixture of TFA (10 ml) and dichloromethane (10 ml) and stirred at ambient temperature overnight. The solution was concentrated and treated with diethylether. The title product was isolated as a white product. Yield 0.87 g (80 %), FAB-MS: 436 (M + 1)

50 Example 6

3,5-Bis-aminomethyl-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoylmethyl-morpholine

a) 3,5-Bis-[1'-(N-methyl-2,6-dioxomorpholine)]-morpholine-4-acetic acid

55 The pentaacid from the example above (0.16 g, 0.36 mmol) was dissolved in pyridine (1.5 ml) and acetic acid anhydride (0.14 g, 1.39 mmol) was added. The mixture was stirred at ambient temperature for 2 hours and added to diethyl ether. The title product was isolated. Yield 0.10g (70%).

b) 3,5-Bis-aminomethyl-N,N',N''-tris-carboxymethyl-N,N''-bis(methyl-carbamoylmethyl)-morpholine

3,5-Bis-[1'-(N-methyl-2,6-dioxomorpholine)]-morpholine-4-acetic acid (0.10 g, 0.25 mmol) was added in portions to a solution of methylamine (40%) in water (10ml) at 0 °C. The solution was stirred overnight at ambient temperature and the solvent was evaporated. Yield 0.112g (97%), FAB/MS: 462 (M + 1).

Example 6.110 3,5-Bis-aminomethyl-N,N',N''-tris-carboxymethyl-N,N''-bis-(N'''-2,3-dihydroxypropyl-N'''-methyl-carbamoylmethyl)-morpholine

3,5-Bis-[1'-(N-methyl-2,6-dioxomorpholine)]-morpholine-4-acetic acid (0.28 g, 0.64 mmol) dissolved in DMA (2 ml), was added to a solution of N-methyl-aminopropane-2,3-diol (0.14 g, 1.3 mmol) in DMA (1.5 ml) at 0 °C under a nitrogen atmosphere. The solution was stirred overnight at ambient temperature and added to a mixture of diethyl ether and chloroform. The title product was isolated as a white solid. Yield 0.37 g (95%), FAB-MS: 611 (M + 1).

Example 6.220 3,5-Bis-aminomethyl-N,N',N''-tris-carboxymethyl-N,N''-bis-(N'''-(5-hydroxy-3-oxa-pentyl)-N'''-methyl-carbamoylmethyl)-morpholine

3,5-Bis-[1'-(N-methyl-2,6-dioxomorpholine)]-morpholine-4-acetic acid (0.30 g, 0.64 mmol) dissolved in DMA (1.5 ml) was added to a solution of 2'-methylamino-2-hydroxy-diethyl ether (prepared in accordance with J. Chem. Soc. London 532 (1947)) (0.038 g, 1.29 mmol) in DMA (0.5 ml) at 0 °C under a nitrogen atmosphere. The solution was stirred overnight at ambient temperature and added to a mixture of diethyl ether and chloroform. The title product was isolated as a white solid. Yield 0.38 g (93%), FAB-MS: 639 (M + 1).

30 Example 72,5-Bis-aminomethyl-pentakis-carboxymethyl-3,4-dihydroxypyrrolidine

2,5-Bis-ethoxycarbonyl-3,4-bishydroxy pyrrol (1.0 g, 4.1 mmol) (prepared in accordance with Tetrahedron Letters 26 1839 (1985)) was dissolved in ethanolic H₂SO₄ (3 %) (50 ml). Rhodium on carbon (5%) (1.0 g) was added and the reduction reaction was allowed to run under hydrogen (9.4 bar) at 80 °C overnight. The catalyst was filtered off and the solvent evaporated. The reaction mixture was dissolved in water, the pH was adjusted with Na₂CO₃ and extracted with dichloromethane. The crude mixture was chromatographed on silica and the title product was isolated. Yield 0.1 g (10 %), FAB-MS: 248 (M + 1).

40 b) 2,5-Bis-carboxamide-3,4-dihydroxypyrrolidine

2,5-Bis-ethoxycarbonyl-3,4-dihydroxypyrrolidine (0.19 g, 0.78 mmol) was dissolved in ethanol saturated with ammonia (60 ml) and heated in an autoclave at 80 °C for 24 hours. The suspension was allowed to cool to ambient temperature before the white crystalline product was filtered off, washed with ethanol and dried under vacuum. Yield: 0.07 g (50%) , mp; 220-225 C. FAB/MS 190 (M + 1)

c) 2,5-Bis-methanamine-3,4-dihydroxypyrrolidine-trihydrochloride

2,5-Bis-carboxamide-3,4-dihydroxypyrrolidine (0.07 g, 0.37 mmol) was dissolved in a solution of borane in THF (40 ml, 1M). The mixture was refluxed overnight and methanol (45 ml) was then added at 0 °C. The solvents were removed. Methanol (15 ml) was again added, and the solution was evaporated. The residue was dissolved in dry ethanol (50 ml), saturated with HCl (g) and heated under reflux for one hour. The suspension was allowed to cool to ambient temperature before the white crystalline product was filtered off, washed with ethanol and dried under vacuum. Yield: 0.07 g (70%), mp 230-240 C FAB-MS 162 (M + 1-3HCl)

d) 2,5-Bis-aminomethyl-pentakis-carboxymethyl-3,4-dihydroxypyrrolidine

The amine hydrochloride from Example 7c (0.70 g, 0.26 mmol) was suspended in dry acetone with dry potassium carbonate (0.65 g, 4.68 mmol) under nitrogen and stirred vigorously for 30 min. A solution of t-butyl bromoacetate (0.61 g, 3.12 mmol) in 1.5 ml acetone was added slowly, and the reaction was stirred overnight at 50 °C. After cooling, the reaction was filtered and the filtrate evaporated to a oil. Yield: 0.02 g. FAB/MS; 733 (M + 1). The oil was dissolved in 0.5 ml methylenechloride and 0.5 ml trifluoroacetic acid was slowly added. After stirring for 2 hours, the solution was evaporated to dryness and the residue was suspended in diethyl ether. The white crystalline product was filtered off, washed with diethyl ether and dried under vacuum. Yield: 0.01g, FAB/MS: 452 (M + 1).

Example 82,3,5,6-Tetrakis-aminomethyl-deca-carboxymethyl-piperazinea) 2,3,5,6-Tetramethoxycarbonylpiperazine

A solution of tetrakis-methoxycarbonylpiperazine (5.3g, 16.9 mmol) (prepared in accordance with J. Org. Chem. 37 (19), p2963 (1972)) in 800 ml of dry ethanol, was hydrogenated at 50 bar in the presence of 10 g 5% palladium on charcoal at 80 °C for 16 hours. After cooling, the solution was filtered and evaporated to give slightly yellow crystals. Yield: 4.8 g (90%), mp. 162-163 °C (Lit. 162-163 °C). NMR confirmed the structure.

b) 2,3,5,6-Tetrakis-aminocarbonyl-piperazine

The tetraester from Example 8a (0.4 g, 1.3 mmol) was dissolved in dry methanol (50 ml), chilled with liquid nitrogen, and liquid ammonia (10 g, 590 mmol) was added. The mixture was stirred in a closed reactor at 50 °C for 2 days. Evaporation of the solvent left a white powder. Yield: 0.308 g (95%), m.p. 215-220 °C (dec.) NMR and IR confirmed the structure.

c) 2,3,5,6-Tetrakis-aminomethyl-piperazineAlternative A:

The tetraamide from Example 8b (0.258 g, 1 mmol) was suspended in 150 ml dry tetrahydrofurane. Freshly generated borane (from boron trifluoride etherate and sodium-borohydride) was bubbled slowly through the suspension with reflux under nitrogen. After the solution became clear (approx. 2 days) it was concentrated in vacuo and the residue hydrolyzed carefully. Water was distilled off in vacuo and the residue was stirred with concentrated hydrochloric acid (20 ml) at 100 °C for 30 minutes. The solution was concentrated to dryness and taken up with conc. sodium hydroxide solution (9ml) and concentrated again to dryness. The residue was extracted with chloroform (6x30ml), the extracts dried, filtered and concentrated to give 69mg (34%) of a yellow oil. FAB/MS: 203 (M + 1).

Alternative B:

Pyrazinetetracarboxamide (2.58 g, 10 mmol) (prepared according to J. Org. Chem. 39(9), p 1235 (1974)) was suspended in 500 ml dry tetrahydrofurane. Freshly generated borane (from boron trifluoride etherate and sodium borohydride) was slowly bubbled through the suspension with reflux under nitrogen. After the solution became clear (approx. 10 days) it was cooled and water added carefully. Concentrated hydrochloric acid was added and the mixture concentrated to dryness in vacuo. The residue was dissolved with 200 ml water, made alkaline (pH 12) by addition of sodium hydroxide pellets and the aqueous solution extracted continuously (3 days) with chloroform. The chloroform phase was concentrated and the residual oil distilled in vacuo (Kugelrohr) to give 1.42 g (65%) clear liquid b.p. 60-80 °C/0.004 mbar. FAB/MS: 219 (M + 1) (Bis-boroamine compound). NMR and IR confirmed the structure. 0.3 g (14 mmol) of this oil is stirred with 5 ml concentrated hydrochloric acid for 12 hours at 100 °C, concentrated in vacuo, dissolved in 5 ml water, made alkaline with sodium hydroxide pellets and the resulting slurry extracted with chloroform (6 x 10 ml). The dried (sodium sulphate) extracts were filtered and

concentrated to yield 110 mg (40%) of a yellow oil.

d) 2,3,5,6-Tetrakis-decacarboxymethyl-aminomethyl-piperazine

5 The hexamine from Example 8c (0.2 g, 1 mmol) is suspended in dry acetone with dry potassium carbonate (1.65 g 12 mmol) under nitrogen and stirred vigorously for 30 min. A solution of t-butyl bromoacetate (1.17 g, 6 mmol) in 1 ml acetone is added slowly, and the reaction is stirred overnight. Another 0.8 g of potassium carbonate is added and the reaction refluxed for 3 hours. After cooling, the reaction is filtered and the filtrate evaporated to a brownish oil, which is purified by chromatography on
10 silica. The oil is dissolved in 5 ml methylene chloride, and 5 ml trifluoroacetic acid is added slowly. After stirring for 2 hours, the solution is evaporated to dryness and the residue taken up in 5 ml 1M HCl. The water phase is washed with chloroform and evaporated to dryness.

Example 9

15

2,5-Bis-aminomethyl-pentakis-carboxymethyl-3-hydroxypyrrolidine

a) 2,5-Bis-ethoxycarbonyl-3-hydroxypyrrolidine

20 2,5-Bis-ethoxycarbonyl-3,4-dihydroxypyrrol (1.0 g, 4.1 mmol) was dissolved in ethanolic H₂SO₄ (3%) (50 ml). Rhodium on carbon (5 %) (1.0 g) was added and the reduction reaction was allowed to run under hydrogen (9.4 bar) at 80 °C overnight. The catalyst was filtered off and the solvent evaporated. The reaction mixture was dissolved in water, the pH was adjusted with Na₂CO₃, and extracted with dichloro-methane. The crude mixture was chromatographed on silica and the title product was isolated. Yield: 0.2 g (21 %),
25 FAB-MS: 232 (M + 1)

b) 2,5-Bis-carboxamide-3-hydroxypyrrolidine

30 2,5-Bis-ethoxycarbonyl-3-hydroxypyrrolidine (0.02 g, 0.08 mmol) was dissolved in ethanol saturated with ammonia (30 ml) and heated in an autoclave at 80 °C for 24 hours before the solvent was evaporated. Yield : 0.01 g (53%). FAB-MS 174 (M + 1)

c) 2,5-Bis-methanamine-3-hydroxypyrrolidine-trihydrochloride

35 2,5-Bis-carboxamide-3-hydroxypyrrolidine (0.15 g, 0.37 mmol) was dissolved in a solution of borane in THF (40 ml, 1M). The mixture was refluxed overnight and methanol (35ml) was then added at 0 °C. The solvents were removed. Methanol (15 ml) was again added, and the solution was evaporated. The residue was dissolved in dry ethanol (50 ml), saturated with HCl (g) and heated under reflux for two hours. The suspension was allowed to cool at ambient temperature before the white crystalline product was filtered off,
40 washed with ethanol, and dried under vacuum. Yield : 0.07 g (41%). FAB-MS 146 (M + 1-3HCl)

d) 2,5-Bis-aminomethyl-pentakis-carboxymethyl-3-hydroxypyrrolidine

45 The amine hydrochloride from Example 9c (0.26 mmol) is suspended in dry acetone with dry potassium carbonate (4.68 mmol) under nitrogen and stirred vigorously for 30 min. A solution of t-butyl bromoacetate (3.12 mmol) in 1.5 ml acetone is added slowly, and the reaction is stirred overnight at 50 °C. After cooling, the reaction is filtered and the filtrate evaporated to a oil. The oil is dissolved in 20 ml methylene chloride and 20 ml trifluoroacetic acid is slowly added. After stirring for 2 hours, the solution is evaporated to dryness and the residue is dissolved in 20 ml 1M HCl. The water phase is washed with chloroform and
50 evaporated to dryness to yield the title compound.

Example 10

55 Sodium salt of a gadolinium (III) chelate of 2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidine

The penta acid from Example 3d A (1.0 g, 2.12 mmol) was dissolved in water, the pH was adjusted to 3.5 with 1 M NaOH and gadolinium oxide (0.67 g, 1.06 mmol) was added. The suspension was reacted for

24 hours under reflux, filtrated, and the filtrate evaporated to dryness to yield 1.2 g (95 %) of a yellow solid. FAB/MS: 625 (M + Na).

Example 11

5

Disodium salt of Dysprosium (III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidine

The same amount of starting material was reacted with dysprosium oxide as described in Example 10. Yield: 1.3 g of a yellow solid (96%). FAB/MS: 653 (N + 2Na).

10

Example 12

Disodium salt of the gadolinium(III)chelate of 3,5-bis-aminomethyl-pentakis-carboxymethyl-morpholine

15

3,5-Bis-aminomethyl-morpholine-pentaacetic acid (0.20 g, 0.23 mmol) was dissolved in water (5 ml), the pH was adjusted to 5 with 1 M sodium hydroxide, and gadolinium(III) oxide (0.086 g, 0.23 mmol) was added. The suspension was stirred overnight at 90 °C, filtered and precipitated with acetone, to give the title product. Yield 0.255 g (94%), FAB-MS 635 (M + 1).

20

Example 13

Gadolinium(III) chelate of 3,5-bis-aminomethyl-N,N',N''-tris-carboxymethyl-N,N''-bis-(methyl-carbamoyl-methyl)-morpholine

25

The bis-amide from Example 6b (0.09 g, 0.20 mmol) was dissolved in water (10 ml), the pH was adjusted to 5 with 1M sodium hydroxide, and gadolinium (III) oxide (0.036 g, 0.10 mmol) was added. The suspension was stirred overnight at 90 °C, filtered and precipitated with acetone, to give the title product. Yield 0.10 g (80%), FAB-MS 617 (M + 1).

30

Example 14

Disodium salt of the dysprosium(III)chelate of 3,5-bis-aminomethyl-N,N,N',N'',N''-pentakis-carboxymethyl-morpholine

35

The penta acid from Example 5e (0.20 g, 0.23 mmol) was dissolved in water (5 ml), the pH was adjusted to 5 with 1 M sodium hydroxide and dysprosium (III) oxide (0.086g, 0.23 mmol) was added. The suspension was stirred overnight at 90 °C, filtered and precipitated with acetone, to give the title product. Yield 0.256 g (94%), FAB-MS 641 (M + 1).

40

Example 15

Bismuth (III) chelate of 2,6-bis-aminomethyl-4-hydroxy--N,N',N''-tris-carboxymethyl-N,N''-bis-methylcarbamoyl-methyl-piperidine,

45

A neutral suspension of bismuth hydroxide is prepared by the neutralisation of a solution of bismuth chloride (0.12 g, 0.38 mmol, 4 ml) with sodium hydroxide, followed by centrifugation of the precipitate and resuspension of the precipitate in water (4 ml). The suspension is added to a neutral solution of bis-amide (0.176g 0.37 mmol) (Example 4) in water (4 ml) and the mixture is refluxed for 4 hours. The clear solution is evaporated, and the title compound is isolated as a white solid.

50

Example 16

Preparation of a solution containing the pentasodium salt of 3,5-bis-aminomethyl-N,N,N',N'',N''-pentakis-carboxymethyl-morpholine

55

The penta acid from Example 5e (1.30 g, 3 mmol) was dissolved in water (15 ml) and the pH was adjusted to 7 by careful addition of 1 M sodium hydroxide. Water was added to 20 ml, the solution was

filtered and then placed into a 20 ml vial. The vial was autoclaved.

The solution contained 0.15 mmol of the pentasodium salt of 3,5-bis-aminomethyl-N,N,N',N'',N''-pentakis-carboxymethyl-morpholine per ml.

The solution is for the treatment of acute or chronic poisoning by heavy metals, such as lead.

5

Example 17

Vial containing the technetium chelate of 3,5-bis-aminomethyl N,N,N',N'',N''-pentakis-carboxymethyl-morpholine

10

A vial is filled with 3,5-bis-aminomethyl-N,N,N',N'',N''-pentakis-carboxymethyl-morpholine from Example 5 (4 mg) and tin (II) chloride (0.22 mg) as dry powder.

A solution of ^{99m}Tc as pertechnetate in 0.9 % sterile sodium chloride should be added before use. The technetium chelate with 3,5-bis-aminomethyl-N,N,N',N'',N''-pentakis-carboxymethyl-morpholine is for the scintigraphic examination of organs such as brain and kidneys. The chelate is also useful for the studying of kidney function.

15

Example 18

Preparation of a solution containing the trisodium salt of the zinc chelate of 2,6-bis-aminomethyl-N,N',N''-pentakis-carboxymethyl-4-hydroxy-piperidine.

20

The penta acid from Example 3d (0.90 g, 2 mmol) and zinc (II) carbonate (0.25 g, 2 mmol) were refluxed for 12 hours in water (15 ml). The mixture was cooled to ambient temperature, and the pH was adjusted to 6 by careful addition of 1 M sodium hydroxide. Water was added to give a volume of 20 ml, the solution was filtered and then placed into a 20 ml vial. The vial was autoclaved. The solution contained 0.1 mmol of the zinc chelate as trisodium salt per ml.

25

The solution may be used for treatment of acute or chronic poisoning by heavy metals, especially radioactive metals such as plutonium.

30

Example 19

Preparation of a solution containing gadolinium (III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidine

35

Gadolinium(III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-pentakis-carboxymethyl-piperidine (6.06 g, 10 mmol) (Example 10) was dissolved in 20 ml of distilled water. The solution was filtered, placed in a 20 ml vial and autoclaved. The solution contained 0.5 mmol gadolinium per ml.

Example 20

Preparation of a solution containing gadolinium (III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoylmethyl-piperidine and 5 % of the sodium salt of the calcium chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoyl-piperidine

45


2,6-Bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoylmethyl-piperidine (0.22 g, 0.5 mmol) (Example 4) and calcium oxide (0.028 g, 0.5 mmol) were refluxed for 12 hours in water (10 ml). The mixture was cooled to ambient temperature and the pH was adjusted to 6.5 by careful addition of 1 M sodium hydroxide. The gadolinium (III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoylmethyl-piperidine (6.06 g, 10 mmol) was added, water was added to a total volume of 20 ml, the solution was filtered and placed into a 20 ml vial. The vial was autoclaved. The solution contained 0.5 mmol of the gadolinium(III) chelate of 2,6-bis-aminomethyl-4-hydroxy-N,N',N''-tris-carboxymethyl-N,N''-bis-methyl-carbamoylmethyl-piperidine per ml.

50


55

Claims

1. A compound of formula I



15 (wherein X represents a bond, an oxygen or sulphur atom or a group of formula CHR¹ or NR³;
 each R¹ which may be the same or different represents a hydrogen atom, a group of formula OR³ or
 NR³R³ or a C₁₋₈alkyl or (C₁₋₈alkoxy)-C₁₋₈alkyl group optionally substituted by a hydroxyl group or by
 a group of formula NR³R³ or CONR³R³;
 20 each R² which may be the same or different represents a hydrogen atom or a C₁₋₈alkyl or C₁₋₈alkoxy
 group optionally mono- or poly- substituted by hydroxyl or C₁₋₈alkoxy groups;
 each R³ which may be the same or different represents a hydrogen atom, an optionally mono- or poly-
 hydroxylated C₁₋₈alkyl group or a group of formula CH₂Y;
 Y represents a group of formula COZ, CON(OH)R⁴, POZ₂ or SO₂Z;
 25 Z represents a group of formula OR⁴, NR⁴R⁴
 or




40 where each R¹¹ which may be the same or different is a hydrogen atom, a hydroxyl group or an optionally
 hydroxylated C₁₋₈alkyl group,
 s is 0, 1 or 2, and
 W is a group CHR¹¹, NR¹¹ or an oxygen atom; and each R⁴ which may be the same or different
 represents a hydrogen atom or an optionally mono- or polyhydroxylated C₁₋₈alkyl, (C₁₋₈alkoxy)-
 45 C₁₋₈alkyl or poly-(C₁₋₈alkoxy)-C₁₋₈alkyl group; with the provisos that where s is 0 then in the resultant
 5 membered heterocyclic ring W is a CHR¹¹ group and that where X represents a bond or a group
 CHR¹ at least one group R¹ or R² represents other than a hydrogen atom or an unsubstituted C₁₋₈alkyl
 group) or a chelate complex or salt thereof.

- 50 2. A compound of formula I as claimed in claim 1 wherein Z represents a group of formula OR⁴ or NR₂⁴
 and each R⁴ which may be the same or different represents a hydrogen atom or an optionally
 hydroxylated alkyl group, or a chelate or salt thereof.

55

3. A compound of formula I as claimed in claim 1 wherein at least one group Z is of formula




or a chelate or salt thereof.


4. A compound of formula I as claimed in claim 1 wherein R¹ represents a hydrogen atom, a hydroxyl group or a hydroxylated alkyl group, R² represents a hydrogen atom or a hydroxylated alkyl group, R³ represents a hydrogen atom or a group of formula CH₂Y, X represents a bond, an oxygen atom, an optionally hydroxylated methylene group or a group NR³, Y represents a group of formula COZ and Z represents a hydroxyl group or a group NHR⁴ (where R⁴ represents a hydrogen atom or an optionally hydroxylated alkyl group), or a metal chelate or salt thereof.

5. A compound as claimed in claim 1 being of formula:


25



(where R⁵ represents CH₂COOH, R⁶ represents CH₂COOH, CH₂CON(CH₃)CH₂CHOHCH₂OH, or CH₂CONHR⁷ and R⁷ represents CH₃, CH₂CHOHCH₂OH or CH(CH₂OH)₂, or NR⁵R⁶ represents a group



- 5 where W represents an oxygen atom or a group CH₂ or CHOH, s is 0 or 1 and R¹¹ is hydrogen or where s is 1 and W is oxygen each R¹¹ may also represent a C₁₋₄ hydroxyalkyl group) or a metal chelate or salt thereof.
6. A Compound as claimed in any of claims 1 to 5 wherein each Y group is a carboxyl group or a salt or
10 amide thereof.
7. A compound as claimed in any one of claims 1 to 6 being a metal chelate of a compound of formula I or a salt thereof.
- 15 8. A compound as claimed in claim 7 wherein the number of ion-forming groups Y is such that the metal chelate is a neutral species.
9. A compound as claimed in either of claims 7 and 8 wherein the chelated metal species is a paramagnetic metal ion having an atomic number of 21-29, 42, 44 or 57-71.
- 20 10. A compound as claimed in claim 9 wherein said paramagnetic metal ion is selected from ions of Eu, Gd, Dy, Ho, Cr, Mn and Fe.
11. A compound as claimed in either of claims 10 and 11 wherein said paramagnetic ion is selected from
25 Gd³⁺, Mn²⁺ and Dy³⁺.
12. A compound as claimed in either of claims 7 and 8 wherein the chelated metal species is a heavy metal ion having an atomic number greater than 37.
- 30 13. A compound as claimed in either of claims 7 and 8 wherein the chelated metal species is a radioactive metal ion.
14. A process for the preparation of compounds as claimed in claim 1, said process comprising at least one of the following steps:
35 a) reacting a compound of formula II




- 40
- 45 (wherein X, R¹ and R² are as defined in claim 1 and R¹⁰ represents a hydrogen atom or a group CH₂Y where Y is as defined in claim 1, with the proviso that at least one hydrogen is nitrogen-attached) with a compound of formula III
- 50 L-CH₂-Y (III)
- (where L is a nucleophilic leaving group); and
- b) converting a compound of formula I into a chelate complex or salt thereof.

- 55 15. A diagnostic or therapeutic agent comprising a physiologically acceptable metal chelate as claimed in any one of claims 1 to 13 or a physiologically acceptable salt thereof, together with at least one pharmaceutical or veterinary carrier or excipient.

16. A detoxification agent comprising a chelating agent as claimed in any one of claims 1 to 6 in the form of a weak complex or salt with a physiologically acceptable counterion, together with at least one pharmaceutical or veterinary carrier or excipient.
- 5 17. A method of generating images of the human or non-human animal body, said method comprising administering to said body a compound or agent as claimed in any of claims 1 to 13 and 16 and generating an X-ray, MR-diagnostic, ultrasound or scintigraphic image of at least a part of said body.
- 10 18. The use of a compound as claimed in any one of claims 1 to 13 for the manufacture of diagnostic or therapeutic agents for use in methods of image generation, detoxification or radiotherapy practised on the human or non-human animal body.
- 15 19. A process for the preparation of metal chelates as claimed in any of claims 1 to 13 said process comprising admixing in a solvent a compound of formula I or a salt or chelate thereof together with an at least sparingly soluble compound of said metal.

Patentansprüche

1. Verbindung der Formel I



(worin X für eine Bindung, ein Sauerstoff- oder Schwefelatom oder eine Gruppe der Formel CHR¹ oder NR³ steht;

jeder der Reste R¹, die gleich oder verschieden sein können, für ein Wasserstoffatom, eine Gruppe der Formel OR³ oder NR³R³ oder für eine C₁₋₈-Alkyl- oder (C₁₋₈-Alkoxy)-C₁₋₈-alkylgruppe steht, die gegebenenfalls substituiert ist mit einer Hydroxylgruppe oder mit einer Gruppe der Formel NH³R³ oder CONR³R³;


jeder der Reste R², die gleich oder verschieden sein können, für ein Wasserstoffatom oder eine C₁₋₈-Alkyl- oder C₁₋₈-Alkoxygruppe steht, die gegebenenfalls durch Hydroxyl- oder C₁₋₈-Alkoxygruppen mono- oder polysubstituiert ist;

jeder der Reste R³, die gleich oder verschieden sein können, für ein Wasserstoffatom, eine gegebenenfalls mono- oder polyhydroxylierte C₁₋₈-Alkylgruppe oder eine Gruppe der Formel CH₂Y steht;

Y für eine Gruppe der Formel COZ, CON(OH)R⁴, POZ₂ oder SO₂Z steht;

Z für eine Gruppe der Formel OR⁴; NR⁴R⁴

oder



steht, worin

jeder der Reste R^{11} , die gleich oder verschieden sein können, für ein Wasserstoffatom, eine Hydroxylgruppe oder eine gegebenenfalls hydroxylierte C_{1-8} -Alkylgruppe steht;
s für 0, 1 oder 2 steht, und

W für eine der Gruppen CHR^{11} , NR^{11} oder für ein Sauerstoffatom steht; und

5 jeder der Reste R^4 , die gleich oder verschieden sein können, für ein Wasserstoffatom oder eine gegebenenfalls mono- oder polyhydroxylierte C_{1-8} -Alkyl-, (C_{1-8} -Alkoxy)- C_{1-8} -alkyl- oder eine Poly- (C_{1-8} -alkoxy)- C_{1-8} -alkylgruppe steht; mit den Maßgaben, daß dann, wenn s für 0 steht, in dem resultierenden 5-gliedrigen heterocyclischen Ring W für eine CHR^{11} -Gruppe steht, und wenn X für eine Bindung oder für eine CHR^1 -Gruppe steht, wenigstens einer der Reste R^1 oder R^2 nicht für ein
10 Wasserstoffatom oder eine unsubstituierte C_{1-8} -Alkylgruppe steht) oder ein Chelatkomplex oder Salz davon.

2. Verbindung der Formel I gemäß Anspruch 1, worin Z für eine Gruppe der Formel OR^4 oder NR^4_2 steht, worin jeder der Reste R^4 , die gleich oder verschieden sein können, für ein Wasserstoffatom oder eine
15 gegebenenfalls hydroxylierte Alkylgruppe steht, oder ein Chelat oder Salz davon.

3. Verbindung der Formel I gemäß Anspruch 1, worin wenigstens eine Gruppe Z eine der folgenden Formeln besitzt


20



25



oder



30

oder ein Chelat oder Salz davon.

4. Verbindung der Formel I gemäß Anspruch 1, worin R^1 für ein Wasserstoffatom, eine Hydroxylgruppe oder eine hydroxylierte Alkylgruppe steht, R^2 für ein Wasserstoffatom oder eine hydroxylierte Alkylgruppe steht, R^3 für ein Wasserstoffatom oder eine Gruppe der Formel CH_2Y steht, X für eine Bindung, ein Sauerstoffatom, eine gegebenenfalls hydroxylierte Methylengruppe oder eine Gruppe NR^3 steht, Y für eine Gruppe der Formel COZ steht und Z für eine Hydroxylgruppe oder eine NHR^4 -Gruppe steht (worin R^4 für ein Wasserstoffatom oder eine gegebenenfalls hydroxylierte Alkylgruppe steht) oder ein
35 Metallchelate oder Salz davon.


40

45

50


55

5. Verbindung gemäß Anspruch 1 mit einer der Formeln:



(worin R⁵ für CH₂COOH, R⁶ für CH₂COOH, CH₂CON(CH₃)CH₂CHOHCH₂OH oder CH₂CONHR⁷ und R⁷ für CH₃, CH₂CHOHCH₂OH oder CH(CH₂OH)₂ steht oder worin NR⁵R⁶ für die Gruppe

35



40

steht, worin W für ein Sauerstoffatom oder eine der Gruppen CH₂ oder CHOH steht, s für 0 oder 1 steht und R¹¹ für ein Wasserstoffatom steht oder worin s für 1 steht und W für ein Sauerstoffatom steht und R¹¹ für eine C₁₋₄-Hydroxyalkylgruppe steht) oder ein Metallchelate oder Salz davon.

45

6. Verbindung nach einem der Ansprüche 1 bis 5, worin jede der Gruppen Y für eine Carboxylgruppe oder ein Salz oder Amid davon steht.

7. Verbindung nach einem der Ansprüche 1 bis 6 in Form eines Metallchelates einer Verbindung der Formel I oder ein Salz davon.

50

8. Verbindung nach Anspruch 7, worin die Anzahl der ionenbildenden Gruppen Y so gewählt ist, daß das Metallchelate eine neutrale Spezies darstellt.

9. Verbindung nach einem der Ansprüche 7 und 8, worin die chelatierte Metallspezies ein paramagnetisches Metallion mit einer Ordnungszahl von 21-29, 42, 44 oder 57-71 ist.

55

10. Verbindung nach Anspruch 9, worin das paramagnetische Metallion ausgewählt ist unter den Ionen von Eu, Gd, Dy, Ho, Cr, Mn und Fe.


11. Verbindung nach einem der Ansprüche 10 und 11, worin das paramagnetische Ion ausgewählt ist unter Gd³⁺, Mn²⁺ und Dy³⁺.

12. Verbindung nach einem der Ansprüche 7 und 8, worin die chelatierte Metallspezies ein Schwermetallion mit einer Ordnungszahl von mehr als 37 ist.

13. Verbindung nach einem der Ansprüche 7 und 8, worin die chelatierte Metallspezies ein radioaktives Metallion ist.

14. Verfahren zur Herstellung von Verbindungen gemäß Anspruch 1, wobei das Verfahren wenigstens einen der folgenden Schritte umfaßt:

a) Umsetzung einer Verbindung der Formel II



(worin X, R¹ und R² die in Anspruch 1 angegebenen Bedeutungen besitzen und R¹⁰ für ein Wasserstoffatom oder eine CH₂Y-Gruppe steht, worin Y die in Anspruch 1 angegebene Bedeutung besitzt, mit der Maßgabe, daß wenigstens ein Wasserstoffatom an Stickstoff gebunden ist) mit einer Verbindung der Formel III

L-CH₂-Y (III)

(worin L für eine nukleophile Abgangsgruppe steht); und

b) die Umsetzung einer Verbindung der Formel I zu einem Chelatkomplex oder Salz davon.

15. Diagnostisches oder therapeutisches Mittel, umfassend ein physiologisch akzeptables Metallchelate gemäß einem der Ansprüche 1 bis 13 oder ein physiologisch akzeptables Salz davon, zusammen mit wenigstens einem pharmazeutischen oder veterinärmedizinischen Träger oder Exzipienten.


16. Entgiftungsmittel, umfassend ein chelatbildendes Mittel gemäß einem der Ansprüche 1 bis 6 in Form eines schwachen Komplexes oder Salzes mit einem physiologisch akzeptablen Gegenion, zusammen mit wenigstens einem pharmazeutischen oder veterinärmedizinischen Träger oder Exzipienten.

17. Verfahren zur Erzeugung von Abbildungen des menschlichen oder nicht-menschlichen, tierischen Körpers, wobei das Verfahren die Verabreichung einer Verbindung oder eines Mittels gemäß einem der Ansprüche 1 bis 13 und 16 an den Körper und die Erzeugung eines Röntgen-, Kernspintogramm-, Ultraschall- oder szintigraphischen Bildes von wenigstens einem Teil des Körpers umfaßt.

18. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 13 zur Herstellung von diagnostischen oder therapeutischen Mitteln zur Verwendung in Verfahren zur Bilderzeugung, Entgiftung oder Autoradiographie, durchgeführt am menschlichen oder nicht-menschlichen, tierischen Körper.

19. Verfahren zur Herstellung eines Metallchelates gemäß einem der Ansprüche 1 bis 13, wobei man bei diesem Verfahren in einem Lösungsmittel eine Verbindung der Formel I oder ein Salz oder Chelat davon, zusammen mit einer wenig löslichen Verbindung des Metalles vermischt.

5




10

ou un chélate ou sel de ce composé.

- 15 4. Composé de formule I tel que revendiqué dans la revendication 1, dans laquelle R¹ représente un atome d'hydrogène, un groupe hydroxyle ou un groupe alkyle hydroxylé, R² représente un atome d'hydrogène ou un groupe alkyle hydroxylé, R³ représente un atome d'hydrogène ou un groupe de formule CH₂Y, X représente une liaison, un atome d'oxygène, un groupe méthylène éventuellement hydroxylé ou un groupe NR³, Y représente un groupe de formule COZ et Z représente un groupe hydroxyle ou un groupe NHR⁴ (où R⁴ représente un atome d'hydrogène ou un groupe alkyle éventuellement hydroxylé), ou un chélate métallique ou un sel dudit composé.
- 20
5. Composé tel que revendiqué dans la revendication 1, répondant à l'une des formules suivantes,


25

30




35

40




45


50



55 dans lesquelles R⁵ représente CH₂COOH, R⁶ représente CH₂COOH, CH₂CON(CH₃)CH₂CHOHCH₂OH ou CH₂CONHR⁷ et R⁷ représente CH₃, CH₂CHOHCH₂OH ou CH(CH₂OH)₂, ou bien NR⁵R⁶ représente un groupe



- 5 où W représente un atome d'oxygène ou un groupe CH₂ ou CHOH, s vaut 0 ou 1 et R¹¹ est l'atome d'hydrogène, ou bien où s vaut 1 et W est l'atome d'oxygène, chaque R¹¹ pouvant également représenter un groupe hydroxyalkyle en C₁₋₄, ou un chélate métallique ou un sel de ce composé.
- 10 6. Composé tel que revendiqué dans l'une quelconque des revendications 1 à 5, dans lequel chaque groupe Y est un groupe carboxyle, ou un sel ou un amide de ce composé.
7. Composé tel que revendiqué dans l'une quelconque des revendications 1 à 6 et qui est un chélate métallique d'un composé de formule I ou d'un de ses sels.
- 15 8. Composé de formule I tel que revendiqué dans la revendication 7, dans lequel le nombre de groupes Y formant des ions est tel que le chélate métallique est une espèce neutre.
9. Composé tel que revendiqué dans l'une quelconque des revendications 7 et 8, dans lequel l'espèce chélatée métallique est un ion métal paramagnétique de numéro atomique 21 à 29, 42, 44 ou 57 à 71.
- 20 10. Composé de formule I tel que revendiqué dans la revendication 9, dans lequel ledit ion métal paramagnétique est choisi parmi les ions de Eu, Gd, Dy, Ho, Cr, Mn et Fe.
- 25 11. Composé tel que revendiqué dans l'une quelconque des revendications 10 et 11, dans lequel ledit ion paramagnétique est choisi parmi Gd³⁺, Mn²⁺ et Dy³⁺.
12. Composé tel que revendiqué dans l'une quelconque des revendications 7 et 8, dans lequel l'espèce chélatée métallique est un ion de métal lourd de numéro atomique supérieur à 37.
- 30 13. Composé tel que revendiqué dans l'une quelconque des revendications 7 et 8, dans lequel l'espèce chélatée métallique est un ion de métal radioactif.
14. Procédé pour la préparation de composés tels que revendiqués dans la revendication 1, qui comprend au moins une des étapes suivantes:
- 35 a) réaction d'un composé de formule suivante II,



50 dans laquelle X, R¹ et R² ont les définitions indiquées dans la revendication 1 et R¹⁰ représente un atome d'hydrogène ou un groupe CH₂Y, où Y est tel que défini dans la revendication 1, sous réserve qu'au moins un atome d'hydrogène soit fixé à l'azote, avec un composé de formule III:



55 dans laquelle L est un groupe partant nucléophile, et

b) transformation d'un composé de formule I en un chélate ou un sel.

15. Agent de diagnostic ou agent thérapeutique comprenant un chélate métallique physiologiquement acceptable, tel que revendiqué dans l'une quelconque des revendications 1 à 13, ou un de ses sels

physiologiquement acceptables, conjointement avec au moins un véhicule ou excipient pharmaceutique ou vétérinaire.

- 5 **16.** Agent de détoxication comprenant un agent chélatant tel que revendiqué dans l'une quelconque des revendications 1 à 6, sous forme d'un complexe ou sel faible avec un contre-ion physiologiquement acceptable, conjointement avec au moins un véhicule ou excipient pharmaceutique ou vétérinaire.
- 10 **17.** Procédé de formation d'images du corps humain ou animal, comprenant l'administration audit corps d'un composé ou agent tel que revendiqué dans l'une quelconque des revendications 1 à 13 et 16, et la formation d'une image de rayons X, de diagnostic RM, d'ultrasons ou de scintigraphie d'au moins une partie dudit corps.
- 15 **18.** Utilisation d'un composé tel que revendiqué dans l'une quelconque des revendications 1 à 13 pour la fabrication d'agents de diagnostic ou thérapeutiques utilisables dans les techniques d'imagerie, de détoxication ou de radiothérapie pratiquées sur le corps humain ou animal.
- 20 **19.** Procédé de préparation de chélates métalliques tels que revendiqués dans l'une quelconque des revendications 1 à 13, qui comprend le mélange dans un solvant d'un composé de formule I ou d'un sel ou chélate de ce composé, conjointement avec au moins un composé faiblement soluble dudit métal.

25

30

35

40

45

50

55